Elizabeth R. Plimack

机构：Fox Chase Cancer Center, Temple University Health System · ORCID：0000-0002-7618-0744

发表论文 782 篇 · 总被引 50094 次 · h-index 81

代表论文

• Feasibility and Characterization of Immune-related Pathologic Response Criteria in Renal Cell Carcinoma (2026 · European Urology Oncology)
• Response-Adapted Bladder Preservation in Muscle-Invasive Bladder Cancer: Results of the Phase II RETAIN-2 Trial and Analysis of ctDNA Dynamics (2026 · medRxiv)
• Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response (2026 · Clinical Genitourinary Cancer)
• Figure S11 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma (2026)
• Figure S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma (2026)
• Table S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma (2026)